Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback